Authors
1
Babylon Oncology Center /Babylon /Iraq.
2
College of Medicine /Baghdad University, Baghdad, Iraq.
,
Document Type : Research Paper
Abstract
BACKGROUND:
Breast cancer is the most common cancer in women. Chemotherapy makes cancer patients at risk of developing myelosuppression which may cause delay in treatment and dose reduction.
AIM OF THE STUDY:
To assess tendency for chemotherapy induced cytopenia after the first cycle of chemotherapy in non-metastatic breast cancer patients.
PATIENTS AND METHODS:
A prospective observational study included 152 patients diagnosed with breast cancer and planned to receive adjuvant chemotherapy in form of Adriamycin / cyclophosphamide (AC) based chemotherapy, all of them with normal complete blood count pre chemotherapy and were observed by recording their absolute neutrophil count, hemoglobin and platelet count for development of cytopenia after three weeks of the first cycle of chemotherapy.
RESULTS:
It is found that 32.2% of patients developed neutropenia with 7.2% of them reached to grade IV neutropenia , 5.9% patients had febrile neutropenia .There’s 23% of patients developed anemia from those 19.1% developed grade I anemia while 3.9% had grade II anemia, and no one experienced thrombocytopenia. Anemia found to be significantly associated with immunohistochemistry status of patients.
CONCLUSION:
Chemotherapy induced neutropenia is a recognized complication on significant number of patients, Anemia is a reported complication but fortunately, it is of grade I or II , Neither patients included in this study developed thrombocytopenia .
- Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst. 1999;91:1616–34.
- Barreto JN, McCullough KB, Ice LL, Smith JA. Antineoplastic agents and the associated myelosuppressive effects: a review. J Pharm Pract. 2014 ;27:440–46.
-
- Off PP, Here S. Abeloff’s Clinical Oncology. Abeloff’s Clinical Oncology. 2020.
- Smith RE. Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. JNCCN J Natl Compr Cancer Netw. 2006;4:649–58.
- Dale DC, McCarter GC, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw. 2003;1:440–54.
- Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52.
- Davita VT, Lawrence TH , Rosenberg SA .cancer principles and practice of oncology .11th edition. United states: Lippincott-Raven Publisher ;2019: 2299-300.
- Palis J. Primitive and definitive erythropoiesis in mammals. Front Physiol. 2014;5:1-9.
- Goldrick A, Olivotto IA, Alexander CS, Speers CH, Barnett J, Allan SJ, et al. Anemia is a Common but Neglected Complication of Adjuvant Chemotherapy for Early Breast Cancer. Curr Oncol. 2007;14:227–33.
- Tia LJP, Lui AGA, Chua NS, Strebel HMJS. Chemotherapy-induced neutropenia, anemia and thrombocytopenia among Filipino breast cancer patients on adjuvant chemotherapy. Acta Med Philipp. 2015;49:26–31.
- Zeuner A, Signore M, Martinetti D, Bartucci M, Peschle C, De Maria R. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res. 2007;67:4767–73.
- NCI-CTC version 2 available from https://www.ncbi.nlm.nih.gov.
- Leonard RCF, Miles D, Thomas R, Nussey F. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer. 2003;89:2062–68.
- Funakoshi T, Latif A GM. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis. Cancer Treat Rev. 2013;39:818–30.
- Chan A, Chen C, Chiang J, Tan SH, Ng R. Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer [Internet]. 2012;20:1525–32. Available from: https://doi.org/10.1007/s00520-011-1241-6
- Schwenkglenks M, Pettengell R, Jackisch C, Paridaens R, Constenla M, Bosly A, et al. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Support Care Cancer [Internet]. 2011;19:483–90. Available from: https://doi.org/10.1007/s00520-010-0840-y.
- V Caggiano, S Gupta RT. Chemotherapy-induced anemia in early-stage breast cancer. J Oncol Pharm Pr. 2001;7:1–6.
- Pourali L, Taghizadeh A, Akhoundi MR, Varshoei F, Zarifian A, Andalibi MSS. Frequency of chemotherapy induced anemia in breast cancer patients. Int J Cancer Manag. 2017;10.
)
